Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer-Reference-Cited by-同舟云学术

Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer

Published:2019-02-27 Issue:4 Volume:10 Page:872-879
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Mori Mio¹^ORCID,Hayashi Hideyuki²,Fukuda Minoru³^ORCID,Honda Sumihisa⁴,Kitazaki Takeshi⁵,Shigematsu Kazuto⁶,Matsuyama Naohiro⁷,Otsubo Mayumi⁷,Nagayasu Takeshi⁸,Hashisako Mikiko⁹,Tabata Kazuhiro⁹,Uetani Masataka²,Ashizawa Kazuto¹³

Affiliation:

1. Department of Clinical OncologyNagasaki University Graduate School of Biomedical Sciences Nagasaki Japan

2. Department of RadiologyNagasaki University Graduate School of Biomedical Sciences Nagasaki Japan

3. Clinical Oncology CenterNagasaki University Hospital Nagasaki Japan

4. Department of Publish Health and Nursing, Public Health and NursingNagasaki University Graduate School of Biomedical Sciences Nagasaki Japan

5. Division of Respiratory Diseases, Department of Internal MedicineJapanese Red Cross, Nagasaki Genbaku Hospital Nagasaki Japan

6. Department of PathologyJapanese Red Cross, Nagasaki Genbaku Hospital Nagasaki Japan

7. Department of RadiologyThe Japanese Red Cross Nagasaki Genbaku Hospital Nagasaki Japan

8. Division of Surgical Oncology, Translational Medical SciencesNagasaki University Graduate School of Biomedical Sciences Nagasaki Japan

9. Department of PathologyNagasaki University Graduate School of Biomedical Sciences Nagasaki Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13017

Reference22 articles.

1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

3. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

4. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?;Expert Opinion on Therapeutic Targets;2024-08-19

2. From spotlight to shadow: ALK inhibitor-induced acute liver failure in a patient with non-small cell lung cancer;Archive of Clinical Cases;2023-12-30

3. Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement;Cancer Imaging;2023-02-23

4. Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib;ESMO Open;2022-12

5. Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: A systematic literature review and meta-analysis;European Journal of Radiology Open;2022